Starpharma Holdings Limited

OTCPK:SPHR.F Stock Report

Market Cap: US$26.1m

Starpharma Holdings Past Earnings Performance

Past criteria checks 0/6

Starpharma Holdings has been growing earnings at an average annual rate of 6.5%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 12.6% per year.

Key information

6.5%

Earnings growth rate

8.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate12.6%
Return on equity-29.0%
Net Margin-83.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Starpharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:SPHR.F Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2410-870
31 Mar 2410-870
31 Dec 2311-870
30 Sep 237-1270
30 Jun 234-1680
31 Mar 235-1680
31 Dec 225-1670
30 Sep 225-1670
30 Jun 225-1670
31 Mar 225-1770
31 Dec 214-1870
30 Sep 214-1970
30 Jun 213-2070
31 Mar 213-1970
31 Dec 203-1960
30 Sep 205-1760
30 Jun 207-1560
31 Mar 207-1463
31 Dec 198-1375
30 Sep 195-1478
30 Jun 193-14610
31 Mar 194-13610
31 Dec 184-11610
30 Sep 185-11510
30 Jun 185-10511
31 Mar 185-12512
31 Dec 174-13513
30 Sep 174-14414
30 Jun 174-15415
31 Dec 161-20417
30 Sep 163-20419
30 Jun 165-21421
31 Mar 165-22521
31 Dec 155-20421
30 Sep 153-20419
30 Jun 152-19416
31 Mar 151-18515
31 Dec 141-18514
30 Sep 141-16512
30 Jun 141-15511
31 Mar 142-1249
31 Dec 132-947

Quality Earnings: SPHR.F is currently unprofitable.

Growing Profit Margin: SPHR.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SPHR.F is unprofitable, but has reduced losses over the past 5 years at a rate of 6.5% per year.

Accelerating Growth: Unable to compare SPHR.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SPHR.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: SPHR.F has a negative Return on Equity (-29.04%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:56
End of Day Share Price 2024/12/18 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Starpharma Holdings Limited is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
Tanushree JainBell Potter
Matthijs SmithCanaccord Genuity